Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Oct 13 - Oct 18
Tremfya (guselkumab) Disease area(s): Immunology Manufacturer(s): Johnson & Johnson 2024 Sales (USD): $3.67 billion Why it sold so well: J&Js IL-23 inhibitor Tremfya experienced significant sales growth last year with $3.67 billion in total sales, an increase of 16.6% from 2023
Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W
The Connection to Adventure and Purpose Frequently Asked Questions Conclusion FAQ Introduction Youve likely curated a supplement stack designed to help you perform better and recover faster
Patients who continue high-calorie, carbohydrate-rich diets or remain sedentary may experience suboptimal results despite taking the medication correctly
Some companies are only looking to make the semaglutide peptide, which is the active ingredient, but more established players are planning to manufacture as well as market the drug. Among the companies planning to tap into the Indian market next year is Lupin, a well-known Indian generic-drug maker
US$ 29.74
US$ 21.97
US$ 21.12
US$ 29.18
US$ 23.32
